Rescue of Prothrombin-deficiency by Transgene Expression in Mice

Summary

Prothrombin has diverse biological functions in addition to its well established role in blood coagulation. In order to study these functions in more detail mouse model systems are needed. Since deficiency of prothrombin in mice results in partial embryonic lethality and neonatal death, alternative approaches are required to study the biology of prothrombin in the adult mouse. The liver is the major site of synthesis of prothrombin and therefore liver-specific promoters were used to express prothrombin in transgenic mice. Mice generated from crosses with these transgenic mice and mice hemizygous for the knock-out allele were used to test whether liver-specific expression is sufficient to correct the phenotype of null mice and whether liver-specific expression is sufficient for the development and survival of mice to adulthood. The mouse albumin promoter/enhancer was used initially for transgene expression without success in obtaining transgene positive, endogenous prothrombin null mice. Two lines of transgene positive, endogenous prothrombin deficient mice were obtained using the mouse transthyretin (TTR) promoter/enhancer driving expression of a human prothrombin cDNA. One line was able to rescue both the embryonic and the neonatal lethality while the other line was only able to correct the embryonic lethality. Expression of prothrombin was restricted to the liver and stomach in one line and to the liver, pancreas, stomach and kidney in the other line of mice. Thrombin activity for one line was determined to be at 5-10% of wildtype levels. These mice developed normally and did not have spontaneous bleeding events unless traumatized. Therefore, transgenic expression of human prothrombin is sufficient for the rescue of the lethality found for prothrombin deficiency in mice.

Keywords

Prothrombin - thrombin - transgenic mice - transthyretin promoter

• References

• 1 Bar-Shavit R, Kahn A, Mann KG, Wilner GD. Identification of a thrombin sequence with growth factor activity on macrophages. Proc Natl Acad Sci USA 1986; 83: 976-80.
• 2 Bar-Shavit R, Hruska KA, Kahn AJ, Wilner GD. Hormone-like activity of human thrombin. Ann New York Acad Sci 1986b 485: 335-48.
• 3 Bar-Shavit R, Hruska KA, Kahn AJ, Wilner GD. Thrombin chemotactic stimulation of HL-60 cells: studies on thrombin responsiveness as a function of differentiation. J Cell Physiol 1987; 31: 255-61.
• 4 Bachhuber BG, Sarembock IJ, Gimple LW, McNamara CA, Owens GK. Thrombin-induced mitogenesis in cultured aortic smooth muscle cells requires prolonged thrombin exposure. Am J Pathol 1995; 286: C1141-7.
• 5 Bar-Shavit R, Benezra M, Eldor A, Hy-am E, Fenton JW, Wlner GD, Vlodavasky I. Thrombin immobilized to extracellular matrix is a potent mitogen for vascular smooth muscle cells: nonenzymatic mode of action. Cell Reg 1990; 01: 453-63.
• 6 Cunningham DD, Farrell DH. Thrombin interactions with cultured fibroblasts: relationship to mitogenic stimulation. Ann NY Acad Sci 1986; 485: 240-8.
• 7 Bar-Shavit R, Eldor A, Vlodavsky I. Binding of thrombin to subendothelial extracelluar matrix: protection and expression of functional properties. J Clin Invest 1989; 84: 1096-104.
• 8 Davey MG, Luscher EF. Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature 1967; 216: 857-8.
• 9 Chen LB, Buchanan JM. Mitogenic activity of blood components. Thrombin and prothrombin. Proc Natl Acad Sci USA 1975; 72: 131-5.
• 10 Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981; 41: 4629-36.
• 11 Dihanich M, Kaser M, Reinhard E, Cunningham D, Monard D. Prothrombin mRNA is expressed by cells of the nervous system. Neuron 1991; 06: 575-81.
• 12 Zimmerman L, Lendahl U, Cunningham M, McKay R, Parr B, Gavin B, Mann J, Vassileva G, McMahon A. Independent regulatory elements in the nestin gene direct transgene expression to neural stem cells or muscle precursors. Neuron 1994; 12: 11-24.
• 13 Festoff BW, Smirnova IV, Ma J, Citron BA. Thrombin, its receptor and protease nexin I, its potent serpin, in the nervous system. Semin Thromb Hemos 1996; 22: 267-71.
• 14 Coughlin S. Thrombin signaling and protease-activated receptors. Nature 2000; 407: 258-64.
• 15 Vu T-KH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-68.
• 16 Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997; 386: 502-6.
• 17 Kahn ML, Zheng Y-W, Huang W, Bigornia V, Zeng D, Moff S, Farese Jr RV, Tam C, Coughlin SR. A dual thrombin receptor system for platelet activation. Nature 1998; 394: 690-4.
• 18 Nakanishi-Matsui M, Zheng Y-W, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 2000; 404: 609-13.
• 19 Barnhart MI. Cellular site for prothrombin synthesis. Am J Physiol 1960; 199: 360-6.
• 20 Jamison CS, Degen SJF. Prenatal and postnatal expression of mRNA coding for rat prothrombin. Biochim Biophys Acta 1991; 1088: 208-16.
• 21 Sun WY, Witte DP, Degen JL, Colbert MC, Burkart MC, Holmback K, Xiao Q, Bugge TH, Degen SJF. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci USA 1998; 95: 7597-602.
• 22 Soifer SJ, Peters KG, O’Keefe J, Coughlin SR. Disparate temporal expression of the prothrombin and thrombin receptor genes during mouse development. Amer J of Path 1994; 144: 60-9.
• 23 Ong K, Horsfall W, Conway EM, Schuh AC. Early embryonic expression of murine coagulation system components. Thromb Haemost 2000; 84: 1023-30.
• 24 Weinstein JR, Gold SJ, Cunningham DD, Gall CM. Cellular localization of thrombin receptor mRNA in rat brain: expression by mesencephalic dopaminergic neurons and codistribution with prothrombin mRNA. J Neurosci 1995; 15: 2906-19.
• 25 Xue J, Wu A, Westfield A, Tuley EA, Lu D, Zhang Q, Shim K, Zheng X, Sadler JE. Incomplete embryonic lethality and fatal neonatal hemorrhage caused by prothrombin deficiency in mice. Proc Natl Acad Sci USA 1998; 95: 7603-7.
• 26 Pinkert CA, Ornitz DM, Brinster RL, Palmiter RD. An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice. Genes Dev 1987; 01: 268-76.
• 27 Heckel JL, Sandgren EP, Degen JL, Palmiter RD, Brinster RL. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 1990; 62: 447-56.
• 28 Costa RH, Van Dyke TA, Yan C, Kuo F, Darnell Jr JE. Similarities in transthyretin gene expression and differences in transcription factors: liver and yolk sac compared to choroid plexus. Proc Natl Acad Sci 1990; 87: 6589-93.
• 29 Yan C, Costa RH, Darnell JE, Chen JD, Van Dyke TA. Distinct positive and negative elements control the limited hepatocyte and choroid plexus expression of transthyretin in transgenic mice. The EMBO J 1990; 09: 869-78.
• 30 Wu H, Wade M, Krall L, Grisham J, Xiong Y, Van Dyke T. Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development and regeneration. Genes & Devel 1996; 10: 245-60.
• 31 Bowman T, Symonds H, Gu L, Yin C, Oren M, Van Dyke T. Tissue-specific inactivation of p53 tumor suppression in the mouse. Genes & Devel 1996; 10: 826-35.
• 32 Degen SJF. Prothrombin. In: Molecular Biology of Thrombosis and Hemostasis. Roberts H, High K. eds. New York: Marcel Dekker, Inc; 1995: 75-99.
• 33 Bezarra JA, Witte DP, Aronow BJ, Degen SJF. Hepatocyte-specific expression of the mouse hepatocyte growth factor-like protein. Hepatology 1993; 18: 394-9.
• 34 Allen-Jennings AE, Hartman MG, Kociba GJ, Hai T. The roles of ATF3 in glucose homeostasis. A transgenic mouse model with liver dysfunction and defects in endocrine pancreas. J Biol Chem 2001; 276: 29507-14.
• 35 Toomey JR, Kratzer KE, Lasky NM, Broze GJ. Effect of tissue factor deficiency on mouse and tumor development. Proc Natl Acad Sci USA 1997; 94: 6922-6.
• 36 Yang TL, Cui J, Taylor JM, Yang A, Gruber SB, Ginsburg D. Rescue of fatal neonatal hemorrhage in Factor V deficient mice by low level transgene expression. Thromb Haemost 2000; 83: 70-7.
• 37 Parry GCN, Erlich JH, Carmeliet P, Luther T, Mackman N. Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest 1998; 101: 560-9.
• 38 Gresele P, Momi S, Berrettini M, Nenci GG, Schwarz HP, Semeraro N, Colucci M. Activated human protein C prevents thrombin-induced thromboembolism in mice: evidence that activated protein C reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. J Clin Invest 1998; 101: 667-76.
• 39 Chambers RC, Leoni P, Blanc-Brude OP, Wembridge DE, Laurent GJ. Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1. J Biol Chem 1000; 275: 35584-91.
• 40 Roberts HR, Lefkowitz JB. Inherited disorders of prothrombin conversion. In: Colman RW, Hirsh J, Marder VJ, Salzman EW. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed. Philadelphia: J.B. Lippincott Co; 1994: 200-18.